| Name | Pramipexole dihydrochloride hydrate |
| Description | Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. |
| In vitro | Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged. |
| In vivo | Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 3.46 mg/mL (11.45 mM), Sonication is recommended.
H2O : 55 mg/mL (181.96 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | transient | tMCAO | syndrome | RLS | restless | recovery | Pramipexole dihydrochloride hydrate | Pramipexole dihydrochloride Hydrate | Pramipexole dihydrochloride | Pramipexole 2HCl | Parkinson's | occlusion | neuroprotection | neurological | middle | legs | Inhibitor | inhibit | DopamineReceptor | Dopamine Receptor | Dopamine | disease | D4 | D3 | D2S | D2L | cerebral | artery |
| Inhibitors Related | Olanzapine | Clozapine N-Oxide | Mirtazapine | Octopamine hydrochloride | Benserazide hydrochloride | L-DOPA | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
